NEW ANTIBODY LINVOSELTAMAB THERAPY SHOWS PROMISE AGAINST MULTIPLE MYELOMA

A new immune- and cancer cell-targeting antibody therapy, linvoseltamab, has shown strong potential to eliminate residual multiple myeloma.

• Interim results from a clinical trial involving 18 patients showed no detectable disease after treatment.
• Findings were presented at the American Society of Hematology (ASH) Annual Meeting in Orlando, US.

Bispecific Antibody: Linvoseltamab

• Participants received up to six cycles of linvoseltamab, a bispecific antibody.
• Highly sensitive tests revealed complete eradication of detectable cancer cells in all patients.
• The therapy may help patients avoid bone marrow transplants, which involve intensive chemotherapy.

How Linvoseltamab Works

• Multiple myeloma originates in plasma cells that accumulate in bone marrow, impairing normal blood function.
• Currently, there is no established cure for the disease.
• Linvoseltamab works by binding to:
  • CD3 — a protein on T cells (immune cells), and
  • BCMA — a protein on multiple myeloma cells.
• By bringing T cells and cancer cells into close contact, it activates the body’s immune system to attack the cancer.

Safety and Side Effects

• Some patients experienced:
  • Neutropenia (low white blood cell count)
  • Upper respiratory infections
• All side effects were within acceptable safety limits, as noted by Kazandjian.

Source: DD News